Clin2
NCT06126406Possibly a fitRecruiting

CEA-targeting CAR-T cell therapy for advanced solid tumors

Gastric CancerColon CancerRectal CancerBreast CancerLung CancerEsophagus CancerCholangiocarcinomaPancreas Cancer

Treatments studied

Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin clinical trials.

This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 or older.
  • You must have advanced colorectal, esophageal, stomach, or pancreatic cancer that has spread or come back after at least two prior treatments.
  • Your tumor must test positive for a protein called CEA (at least 10% of cells show it, and your blood CEA level must be above a certain threshold).
  • You must have at least one tumor that can be measured on a scan (like a CT or MRI).
  • You must be in fairly good overall health (able to do daily activities, with adequate blood counts and heart, kidney, and liver function).
  • You cannot have untreated brain metastases, active infections, serious heart problems, or other active cancers.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07179692Recruiting· Phase 1
CEA-targeted CAR-T therapy for advanced solid tumors

This trial tests a type of immunotherapy called CAR-T, which is designed to recognize and attack cancer cells that have a protein called CEA on their surface. It's for people with advanced cancers like colorectal, esophageal, gastric, pancreatic, lung, or bile duct cancer who have tried at least two standard treatments.

Hefei, Anhui
NCT06043466Recruiting· Phase 1
CAR-T cell therapy for CEA-positive advanced solid tumors

This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.

Hangzhou, Zhejiang
NCT07250386Recruiting· Phase 1
CEA-targeted CAR-T therapy for advanced solid tumors

This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.

Hangzhou, Zhejiang
NCT06006390Recruiting· Phase 1/Phase 2
CAR-T therapy for CEA-positive advanced solid tumors

This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.

Taiyuan, Shanxi
NCT06010862Recruiting· Phase 1
CAR-T therapy for CEA-positive advanced cancers

This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.

Nanchang, Jiangxi
NCT06821048Recruiting· Phase 1
CAR-T cells targeting CEA for advanced solid tumors

This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.

Hangzhou, Zhejiang

Hear when a new Gastric Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.